What is the recommended endoscopic biopsy protocol, Helicobacter pylori testing and eradication regimen, and surveillance schedule for gastric intestinal metaplasia?

Management of Gastric Intestinal Metaplasia

For patients with gastric intestinal metaplasia, obtain a minimum of 5 biopsies using the updated Sydney System protocol (2 from antrum/incisura and 2 from corpus in separate jars, plus any suspicious areas), test and eradicate H. pylori in all cases, and implement risk-stratified surveillance every 3 years for those with severe atrophic gastritis and/or multifocal or incomplete GIM, particularly if additional risk factors are present. 1

Endoscopic Biopsy Protocol

The systematic biopsy approach is critical for accurate staging and risk stratification:

• Minimum 5 total biopsies required using the updated Sydney System protocol 1
• Jar 1: 2 biopsies from antrum/incisura
• Jar 2: 2 biopsies from corpus
• Separate jar: Any endoscopically suspicious areas must be described and biopsied separately 1

Use high-definition white-light endoscopy with image enhancement (narrow band imaging or linked color imaging) to guide biopsy sites, as these technologies achieve >85-90% sensitivity and specificity for detecting GIM 1. Ensure adequate gastric mucosal cleansing, proper insufflation, adequate inspection time, and systematic photodocumentation 1.

Pathology Reporting Requirements

Work with your pathologist to ensure consistent documentation of 1:

• Presence or absence of H. pylori infection
• Severity of atrophy and/or metaplasia
• Histologic subtyping of GIM (complete vs. incomplete)
• Anatomic extent (antrum only vs. multifocal involving corpus)

H. Pylori Testing and Eradication

Test all patients with GIM for H. pylori and eradicate if positive 1. This is non-negotiable and serves as both primary and secondary prevention of gastric cancer.

Key Principles:

• H. pylori eradication is essential but adjunctive to endoscopic surveillance—it does not replace the need for surveillance in patients with established GIM 1
• The greatest benefit occurs before precancerous changes develop (63% risk reduction vs. 43% after changes are present) 1
• Confirm eradication after treatment—persistent infection increases risk of progression 1
• Consider familial-based testing in adult household members of H. pylori-positive individuals 1

Common Pitfall:

Do not assume H. pylori eradication alone is sufficient—patients with established histologic changes remain at risk for neoplastic progression even after successful eradication and require ongoing surveillance 1.

Surveillance Schedule: Risk-Stratified Approach

HIGH-RISK: Surveillance Every 3 Years

Perform surveillance endoscopy every 3 years in patients with 1:

• Severe atrophic gastritis, AND/OR
• Multifocal GIM (involving both antrum and corpus), AND/OR
• Incomplete GIM subtype

Consider shorter intervals (potentially more frequent than 3 years) if multiple risk factors coexist, such as 1:

• Family history of gastric cancer in first-degree relative
• Anatomically extensive severe GIM
• Persistent H. pylori despite eradication attempts
• First-generation immigrant from high-incidence gastric cancer region

LOWER-RISK: Surveillance Generally Not Recommended

Routine surveillance is not recommended for patients with 1, 2:

• Mild to moderate atrophy restricted to antrum only
• GIM at single anatomic location (antrum/incisura only)
• Absence of other risk factors

However, surveillance MAY be considered (shared decision-making) every 3 years for single-location GIM if 2:

• Family history of gastric cancer in first-degree relative, OR
• Incomplete GIM subtype, OR
• Persistent H. pylori gastritis despite treatment

NO FINDINGS AT INDEX ENDOSCOPY

If the initial screening endoscopy in a high-risk individual shows no atrophy, GIM, or neoplasia 1:

• Decision to continue screening depends on individual risk factors
• If family history of gastric cancer or multiple risk factors present, consider ongoing screening every 3-5 years
• Optimal intervals are not well-defined in this scenario 1

Special Considerations for Dysplasia

If indefinite or low-grade dysplasia is identified 1:

• Confirm with experienced GI pathologist
• If H. pylori positive, eradicate and confirm eradication
• Repeat endoscopy by experienced endoscopist after inflammation subsides
• Refer to center with expertise in gastric neoplasia management

If high-grade dysplasia or early gastric cancer 1:

• Refer immediately to center with endoscopic submucosal dissection expertise
• Goal is en bloc R0 resection for accurate staging and curative intent
• Eradicate H. pylori but do not delay endoscopic intervention

Quality Measures

To maximize detection and accurate staging 1:

• Use high-definition endoscopy systems
• Apply image enhancement (narrow band imaging, linked color imaging)
• Perform gastric mucosal cleansing before examination
• Ensure adequate inspection time
• Systematic photodocumentation of findings
• Recognize that GIM and dysplasia are endoscopically detectable when proper technique is used 1

Critical Caveat:

Only pursue screening and surveillance in patients who are fit for endoscopic or surgical treatment if neoplasia is detected—if a patient is no longer fit for intervention, screening and surveillance should be discontinued 1.